Clinical Glomerulonephritis 2

7 Feb 2025 5:30 p.m. 6:30 p.m.

Time	Session

12 a.m. 12 a.m.	INFECTION-RELATED GLOMERULONEPHRITIS OUTCOMES IN PATIENTS WITH AND WITHOUT DIABETES MELLITUS (IGOD) WCN25-AB-4087, Poster Board= FRI-175	IGA DOMINANT INFECTION RELATED GLOMERULONEPHRITIS WCN25-AB-1128, Poster Board= FRI-176	CLINICAL PRESENTATION OF THE FAMILIAL CASES OF ANCA-ASSOCIATED VASCULITIS: A SYSTEMATIC REVIEW WCN25-AB-4130, Poster Board= FRI-177	PERFORMANCE OF THE DIFFERENT PREDICTION TOOLS FOR ANCA-ASSOCIATED GLOMERULONEPHRITIS: A RETROSPECTIVE COHORT STUDY WCN25-AB-266, Poster Board= FRI-178	EVALUATION OF TREATMENT STRATEGY IN PATIENTS WITH IGA NEPHROPATHY WITH IMPAIRED RENAL FUNCTION WCN25-AB-2007, Poster Board= FRI-179	EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IGA NEPHROPATHY (IGAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IGAN STUDY WCN25-AB-716, Poster Board= FRI-180	SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN) WITH BASELINE EGFR 20-<30 ML/MIN: PHASE 3 APPLAUSE-IGAN SUBCOHORT RESULTS WCN25-AB-797, Poster Board= FRI-181	EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IGAN STUDY WCN25-AB-799, Poster Board= FRI-182	CLINICAL AND LABORATORY DISTINCTIONS IN PRIMARY VS. SECONDARY MEMBRANOUS NEPHROPATHY: INSIGHTS FROM WESTERN MEXICO WCN25-AB-2758, Poster Board= FRI-183	IMPACT OF DEMOGRAPHIC AND SOCIO-ECONOMIC FACTORS ON INFECTIVE COMPLICATIONS AND OUTCOMES IN LUPUS NEPHRITIS WCN25-AB-2524, Poster Board= FRI-184	RENAL-LOSS HYPOKALEMIA COMPLICATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS PRESENTING AS NEPHROTIC SYNDROME: A RARE CASE WCN25-AB-2069, Poster Board= FRI-185	PROGNOSTIC OF THE PERSISTENCE OF HEMATURIA AND PROTEINURIA AFTER INDUCTION IN VASCULITIS ASSOCIATED WITH ANCA IN THE NEPHROLOGY SERVICE, HOSPITAL DE CLÍNICAS UNIVERSITARIO, BOLIVIA. WCN25-AB-945, Poster Board= FRI-186	THE ROLE OF RITUXIMAB IN ANTI-GBM: CASE REPORT WCN25-AB-1012, Poster Board= FRI-187	A DIAGNOSTIC CHALLENGE CASE REPORT: C3-GLOMERULONEPHRITIS IN A 17-YEAR-OLD ADOLESCENT WCN25-AB-1789, Poster Board= FRI-188	EFFECT OF DAPAGLIFLOZIN AT 12 MONTHS ON KIDNEY FUNCTION IN PATIENTS WITH GLOMERULAR DISEASE IN THE MAINTENANCE PHASE OF THE POPULATION OF THE REGIONAL GENERAL HOSPITAL 46 OF THE MEXICAN INSTITUTE OF SOCIAL SECURITY WCN25-AB-2908, Poster Board= FRI-189	FELZARTAMAB FOR IGA NEPHROPATHY: FINAL RESULTS OF THE IGNAZ STUDY WCN25-AB-844, Poster Board= FRI-190	FACTORS ASSOCIATED WITH RENAL RESPONSE ACHIEVEMENT IN MONOCLONAL IMMUNOGLOBULIN RELATED GLOMERULOPATHIES WCN25-AB-3550, Poster Board= FRI-191	MOLECULAR ALTERATIONS OF PODOCYTES IN PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND IMMUNOGLOBULIN A NEPHROPATHY: AN EXPLORATORY STUDY WCN25-AB-3115, Poster Board= FRI-192	IMMUNOSUPPRESSION COMBINED WITH TONSILLECTOMY IS EFFECTIVE IN CAUCASIAN PATIENTS WITH HIGH-RISK PRIMARY IGA-NEPHROPATHY WCN25-AB-3017, Poster Board= FRI-193	UNCOMMON PRESENTATION OF MULTIPLE MYELOMA (MM): ATYPICAL MANIFESTATION OF KIDNEY DISEASE WCN25-AB-2399, Poster Board= FRI-194	RITUXIMAB IN PRIMARY MEMBRANOUS NEPHROPATHY- THREE YEARS OUTCOME WCN25-AB-4122, Poster Board= FRI-195	IMPROVED OUTCOMES WITH AN ADDITIONAL RITUXIMAB DOSE IN PRIMARY MEMBRANOUS NEPHROPATHY WCN25-AB-4036, Poster Board= FRI-196	LOW-DOSE VERSUS STANDARD-DOSE CYCLICAL CYCLOPHOSPHAMIDE AND STEROIDS IN THE TREATMENT OF PRIMARY MEMBRANOUS NEPHROPATHY- A RANDOMIZED CONTROLLED TRIAL WCN25-AB-2664, Poster Board= FRI-197